---
title: "Descartes-08 in Generalized myasthenia gravis: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Place in treatment, anticipated use, and care setting. Topics: Company statement of unmet need with chronic immunosuppression and continually administered biologics, Company estimate of the U.S. myasthenia gravis population and market opportunity, Positioning as an outpatient CAR-T without preconditioning chemotherapy, Care setting compared with conventional DNA-based CAR-T cell therapy, and 14 further topics. 19 evidence topics quoted from 24 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary

- Guideline positioning of targeted biologics: Guidance states that clinicians should seek to initiate available targeted therapies in patients with gMG who have active symptoms and for whom conventional therapy does not achieve symptom control within 6 to 12 months or results in excessive treatment-related burden, with use as initial treatment driven by clinician judgment. Complement and FcRn inhibitors are recommended as second- or third-line treatment in severe MG exacerbations and crisis, and their roles are being established especially in patients unresponsive to conventional therapy. Expert recommendations state that an interclass switch should be considered for inefficacy, intolerable side effects, or patient preferences regarding type and frequency of administration, and that a switch to IVIg interval therapy should be considered when targeted immunotherapies fail.
- Intended population and setting for Descartes-08: The phase 3 AURORA trial enrolls adults with acetylcholine receptor autoantibody-positive generalized MG and administers six once-weekly outpatient infusions without preconditioning chemotherapy. The company states that the current standard of care consists of chronic steroids and other immunosuppressants and that complement and FcRn inhibitors are typically administered continually, estimates that MG affects over 106,000 patients in the U.S., and describes Descartes-08 as the only CAR-T in autoimmune disease it is aware of that is designed for outpatient administration without preconditioning chemotherapy. The company states that conventional DNA cell therapies are administered under close monitoring in an inpatient setting. Investigators of an earlier Descartes-08 study reported the feasibility of preparing the cells for patients on immunosuppressive therapy, using them without lymphodepletion chemotherapy, and administering them in the outpatient setting with minimal post-infusion monitoring, and a later publication describes a “biologic-like approach that involves an initial leukapheresis”. An investigator quoted by the company described outpatient retreatment without lymphodepleting chemotherapy as a potential option for patients who have cycled through multiple therapies.
- Recommendations on cellular therapy: EBMT recommendations state that cellular therapy in autoimmune diseases should be performed within a clinical trial whenever possible, at expert centres with JACIE accreditation for immune effector cell administration, that the need for and dose of lymphodepletion are not established, and that repeated dosing of BCMA CAR-T has been efficacious in MG without lymphodepletion. A 2026 article on CAR-T therapy in autoimmune disease states that current neurological evidence is limited to small early-phase studies and case reports, with one placebo-controlled trial (generalised MG), and that CAR-T therapy should be considered experimental and delivered in specialised centres.
- Other CAR-T approaches in MG: In a study of anti-BCMA/CD19 bispecific CAR-T cells given as a single infusion after fludarabine and cyclophosphamide lymphodepletion, 18 participants were enrolled; grade 1 cytokine release syndrome occurred in 39%, and among 17 who completed follow-up, MG-ADL improved by −8.6 (95% CI −10.2 to −7.0) and QMG by −15.4 (−17.6 to −13.2) by day 180, and 14 (82%) achieved minimal manifestations. Three patients with treatment-resistant MG treated with anti-CD19 CAR-T cells (KYV-101) after cyclophosphamide and fludarabine lymphodepletion achieved sustained remission for at least 19 months, and BCMA-directed CAR-T cells in two patients (one AChR-IgG, one MuSK-IgG) produced clinical improvement over 18 months. KYV-101 is being compared with standard-of-care immunosuppressive therapy in the phase 2/3 KYSA-6 study, and CABA-201 is being evaluated with cyclophosphamide and fludarabine and, at escalating doses, without that preconditioning.
- REMS change for approved CAR-T therapies: The FDA eliminated the REMS for currently approved BCMA- and CD19-directed autologous CAR T cell immunotherapies, removing the requirements for specially certified dispensing sites with on-site, immediate access to tocilizumab. Labeling now calls for monitoring for at least two weeks, including daily monitoring for at least one week, remaining near a healthcare facility for at least two weeks, and avoiding driving for two weeks. In 58 patients with myeloma, lymphoma, or acute lymphoblastic leukemia who received CAR T-cell infusion as outpatients and were seen daily for the first 7 to 10 days, 17 (41%), 16 (38%), and 9 (21%) were admitted between days 0 to 3, 4 to 7, and 8 to 30.

Source: [Narayanaswami et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13352217/); [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/); [Jacob et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40940171/); [Meisel et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13559022/); [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247); [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial); [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm); [Cartesian Therapeutics K2 HealthVentures financing press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-secures-150-million-non-dilutive); [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/); [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/); [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data); [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/); [Bradhurst et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13630046/); [Zhang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12615342/); [Hegelmaier et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13589498/); [Tian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11018773/); [ClinicalTrials.gov NCT06193889](https://clinicaltrials.gov/study/NCT06193889); [ClinicalTrials.gov NCT06359041](https://clinicaltrials.gov/study/NCT06359041); [FDA news release on CAR T cell REMS elimination (2025)](https://www.fda.gov/news-events/press-announcements/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor); [FDA safety communication on CAR T cell REMS elimination (2025)](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor); [Furqan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11372811/)

<a id="topic-2.2.2.2-2"></a>

### Company statement of unmet need with chronic immunosuppression and continually administered biologics

> “There are no known cures for MG and the current standard of care consists of chronic use of steroids and other immunosuppressants.”
> “These treatments must be administered continually and carry risks such as infection, osteoporosis, and metabolic diseases.”
> “Newer agents, such as those that block the complement pathway or inhibit FcRn, are typically administered continually.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.2.2.2-3"></a>

### Company estimate of the U.S. myasthenia gravis population and market opportunity

> “It is estimated to affect over 106,000 patients in the U.S.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

> “Current gMG market lacks disease modifying treatments creating the potential to access a $1B+ market opportunity for Descartes-08 in the US”
> “Significant unmet need remains given current treatment options, creating a potential $1B opportunity”

Source: [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)

<a id="topic-2.2.2.2-4"></a>

### Positioning as an outpatient CAR-T without preconditioning chemotherapy

> “Descartes-08 remains the only CAR-T in autoimmune disease that we are aware of that is designed for outpatient administration without preconditioning chemotherapy, and our prior data demonstrate deep and durable responses after a single course of therapy.”

Source: [Cartesian Therapeutics K2 HealthVentures financing press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-secures-150-million-non-dilutive)

> “We believe this profile has the potential to meaningfully change how MG is treated.”

Source: [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial)

<a id="topic-2.2.2.2-5"></a>

### Care setting compared with conventional DNA-based CAR-T cell therapy

> “Given these risks and requirements, conventional DNA cell therapies are administered under close monitoring in an inpatient setting, increasing their cost and limiting their reach to only the sickest patients.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

> “This study demonstrated the feasibility of preparing autologous RNA CAR T-cells (rCAR-T) for patients on immunosuppressive therapy, of using the cells without lymphodepletion chemotherapy, and of administering rCAR-T in the outpatient setting with minimal post-infusion monitoring due to the notable safety profile of the product.”
> “While DNA-based CAR T-cell therapies are also moving to the outpatient setting, they still require close post-infusion monitoring with daily clinic visits as well as reservation of hospital beds in case severe toxicities develop.”

Source: [Granit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10416207/)

> “This set of features creates a biologic-like approach that involves an initial leukapheresis but is otherwise similar with respect to patient experience.”

Source: [Fedak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13004674/)

<a id="topic-2.2.2.2-6"></a>

### Investigator statement on use after multiple prior therapies

> “For patients who have already cycled through multiple therapies, the option to retreat a CAR-T cell therapy, in an outpatient setting and without lymphodepleting chemotherapy, represents an exciting potential advancement in the field of MG.”

Source: [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data)

<a id="topic-2.2.2.2-7"></a>

### Guideline positioning of complement and FcRn therapies

> “several clinical trials have been published for newer targeted therapies in MG, predominantly those that inhibit the complement and neonatal Fc gamma receptor pathways, the roles of which are being slowly established especially in patients unresponsive to conventional therapy.”

Source: [Jacob et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40940171/)

> “Complement and FcRn inhibitors are recommended as second‐ or third‐line treatment in severe MG exacerbations and crisis.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.2-8"></a>

### Targeted therapies after 6 to 12 months of conventional therapy without symptom control: 2026 international consensus

> “Clinicians should seek to initiate available targeted therapies* in patients with gMG who have active symptoms and for whom conventional therapy† does not achieve symptom control within 6–12 months or results in excessive treatment-related burden. Use of available targeted therapies as initial treatment (together with standard therapy where indicated) should be driven by clinician judgment.”
> “Clinicians should refer a patient with MG to (or comanage with) a specialist with expertise in MG management if there is no sustained clinical improvement within 3–6 months of treatment initiation.”

Source: [Narayanaswami et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13352217/)

<a id="topic-2.2.2.2-9"></a>

### Switching after inadequate response to targeted therapies: German-Austrian expert recommendations

> “Recommendation (consensus): An interclass switch should be considered if therapy is ineffective at the appropriate dosage and duration, if intolerable side effects occur, or for patient preferences regarding type and frequency of administration.”
> “Recommendation (strong consensus): A switch to IVIg interval therapy should be considered in cases where targeted immunotherapies fail to provide adequate clinical efficacy.”
> “Recommendation (strong consensus): Patients who are clinically stable on IVIg or SCIg interval therapy without intolerable side effects should not be switched to C5‐I or FcRn‐I.”

Source: [Meisel et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13559022/)

<a id="topic-2.2.2.2-10"></a>

### Cellular therapy for severe refractory autoimmune disease within clinical trials at accredited centers: EBMT recommendations

> “Whenever possible, CT in ADs should be performed in the context of a clinical trial with well-defined end points and eligibility criteria in accordance with GCPs and appropriate regulatory requirements.”
> “Such expert centres should have a JACIE accreditation for Immune Effector Cells (IEC) administration and established multidisciplinary team meetings and/or similar processes for CT as for HCT, involving AD specialists and haematologists working in tandem in the same place to support thorough assessment, treatment and follow-up of these high-risk fragile patients.”

Source: [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)

<a id="topic-2.2.2.2-11"></a>

### Lymphodepletion requirement for CAR T-cell therapy in autoimmune disease not established: EBMT recommendations

> “Of note, repeated dosing of BCMA CART has been efficacious in MG without LD”
> “If and at what dose LD is needed for effective CART in AD is currently not established. As such, LD follows oncological guidelines.”

Source: [Greco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10867419/)

<a id="topic-2.2.2.2-12"></a>

### CAR T-cell therapy in autoimmune neurological disease: experimental status, specialized centers, and complications

> “Possible complications from CAR-T cells (box 1) are extensive and limit the use of these therapies to patients with ‘severe’ or ‘refractory’ autoimmune disease that is not otherwise responsive to existing treatment paradigms.”
> “Current neurological evidence is limited to small early-phase studies and case reports, with only one placebo-controlled trial (generalised myasthenia gravis).”
> “At present, CAR-T therapy should be considered experimental and delivered in specialised centres, pending longer term safety and durability data.”

Source: [Bradhurst et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13630046/)

<a id="topic-2.2.2.2-13"></a>

### BCMA/CD19 bispecific CAR T-cell therapy after fludarabine and cyclophosphamide lymphodepletion: single-arm phase 1 trial, 18 participants with refractory gMG

> “Participants received lymphodepleting chemotherapy with fludarabine (30 mg/m2/day) and cyclophosphamide (300 mg/m2/day) for three consecutive days (days −5 to −3).”
> “Between May 3, 2023, and June 19, 2024, 18 patients were enrolled and received apheresis and a single CAR T cell infusion.”
> “The anti-BCMA/CD19 bispecific CAR T cells were generally safe, with no dose-limiting toxicities, no immune effector cell-associated neurotoxicity syndrome, and only grade 1 cytokine release syndrome (39% of patients). The most common grade 3 or worse adverse events within 28 days were hematological toxicities, including three leukopenia, three neutropenia, one anaemia, and one thrombocytopenia.”
> “17 participants completed follow-up. Clinical improvements by day 180 were −8.6 (95% CI −10.2 to −7.0) for MG-ADL score and −15.4 (−17.6 to −13.2) for QMG score. 14 participants (82%) achieved minimal manifestations, 15 (88%) stopped glucocorticoids, all stopped non-steroidal immunosuppressants, and eight (47%) had anti-acetylcholine receptor antibody negative seroconversion.”

Source: [Zhang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12615342/)

<a id="topic-2.2.2.2-14"></a>

### CD19 CAR T-cell therapy after lymphodepletion: case series of 3 participants with refractory AChR antibody-positive MG

> “We report on three patients with severe, treatment-resistant MG, including one patient with concomitant rheumatoid arthritis, treated with autologous, fully human anti-CD19 CAR T cells. All three patients achieve rapid, sustained clinical MG remission for at least 19 months, allowing discontinuation of MG-specific immunotherapies and substantial improvement in clinical and functional outcomes despite persistent detectable anti-AChR autoantibody titers.”
> “A second-generation investigational CAR T cell product (KYV-101, Kyverna Therapeutics) was used.”
> “Instead, it may at least partially be attributed to the effects of lymphodepletion (cyclophosphamide and fludarabine), which from approximately day −6 before CAR T cell infusion markedly reduces circulating immune effector cells capable of mediating antibody-dependent inflammation.”

Source: [Hegelmaier et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13589498/)

<a id="topic-2.2.2.2-15"></a>

### BCMA CAR T-cell therapy after lymphodepletion: 2 participants with refractory AChR or MuSK antibody-positive MG

> “We reported here chimeric antigen receptor (CAR) T cells targeting BCMA in two patients with highly relapsed and refractory myasthenia gravis (one with AChR-IgG, and one with MuSk-IgG). Both patients exhibited favorable safety profiles and persistent clinical improvements over 18 months.”
> “Participants stopped all immunosuppressants and steroid one to three days before treatment initiation.”

Source: [Tian et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11018773/)

<a id="topic-2.2.2.2-16"></a>

### CD19 CAR T-cell therapy in concomitant MG and Lambert-Eaton myasthenic syndrome: 2 participants

> “Two women diagnosed with concomitant MG/LEMS experienced severe, increasing disease activity despite multiple immunotherapies.”
> “Within 2 months, both patients returned to everyday life, from wheelchair dependency to bicycling and mountain hiking, and remain stable at 6 and 4 months post-CAR T cell infusion, respectively.”

Source: [Motte et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38697115/)

<a id="topic-2.2.2.2-17"></a>

### Ongoing CD19 CAR T-cell trials in gMG with and without lymphodepletion: KYSA-6 and RESET-MG

> “KYSA-6: A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients With Generalized Myasthenia Gravis”

Source: [ClinicalTrials.gov NCT06193889](https://clinicaltrials.gov/study/NCT06193889)

> “A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated. In addition, escalating doses of CABA-201 will be evaluated in patients without CY and FLU preconditioning.”

Source: [ClinicalTrials.gov NCT06359041](https://clinicaltrials.gov/study/NCT06359041)

<a id="topic-2.2.2.2-18"></a>

### FDA elimination of REMS for approved autologous CAR T-cell therapies, June 2025

> “The U.S. Food and Drug Administration announced today that it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor CAR T cell immunotherapies.”
> “The elimination of REMS for the above products removes the requirements that hospitals and their associated clinics that dispense products must be specially certified and have on-site, immediate access to tocilizumab.”

Source: [FDA news release on CAR T cell REMS elimination (2025)](https://www.fda.gov/news-events/press-announcements/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor)

> “Specifically, labeling update included revision to language to monitor patients for at least two weeks including daily monitoring for at least one week; to instruct patients to remain within proximity of a healthcare facility for at least two weeks; and to advise patients to avoid driving for two weeks following product administration”
> “FDA expects that the REMS elimination, and these labeling updates, will help improve access to these products, particularly for patients who live in rural areas, while ensuring safe and effective administration to patients who need them.”

Source: [FDA safety communication on CAR T cell REMS elimination (2025)](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor)

<a id="topic-2.2.2.2-19"></a>

### Outpatient administration of commercial CAR T-cell therapy in hematologic malignancies: 58 participants, 2022 to 2023

> “Patients were seen daily in the cancer center day hospital for the first 7 to 10 days and then twice weekly through day 30.”
> “Fifty-eight patients received outpatient CAR T-cell infusion (33 myeloma, 24 lymphoma, and 1 acute lymphoblastic leukemia). Of these, 17 (41%), 16 (38%), and 9 patients (21%) were admitted between days 0 to 3, 4 to 7, and 8 to 30 after CAR T-cell infusion, respectively.”
> “Hospitalization was prevented in 15 of 35 patients who received tocilizumab for CRS as an outpatient.”

Source: [Furqan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11372811/)

Additional sources: [Haghikia et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37977704/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
